Johnson & Johnson $JNJ Stock Holdings Reduced by Dogwood Wealth Management LLC

Dogwood Wealth Management LLC lowered its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 31.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,389 shares of the company's stock after selling 1,552 shares during the quarter. Dogwood Wealth Management LLC's holdings in Johnson & Johnson were worth $528,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Brighton Jones LLC boosted its stake in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Financial Management Professionals Inc. grew its holdings in Johnson & Johnson by 24.4% in the 1st quarter. Financial Management Professionals Inc. now owns 917 shares of the company's stock valued at $152,000 after buying an additional 180 shares during the last quarter. Matrix Trust Co increased its position in Johnson & Johnson by 17.5% in the 1st quarter. Matrix Trust Co now owns 982 shares of the company's stock worth $163,000 after buying an additional 146 shares during the period. Lifestyle Asset Management Inc. increased its position in Johnson & Johnson by 7.1% in the 1st quarter. Lifestyle Asset Management Inc. now owns 1,671 shares of the company's stock worth $277,000 after buying an additional 111 shares during the period. Finally, Channel Wealth LLC increased its position in Johnson & Johnson by 3.4% in the 1st quarter. Channel Wealth LLC now owns 4,813 shares of the company's stock worth $798,000 after buying an additional 158 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. Citigroup lifted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Royal Bank Of Canada lifted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Bank of America boosted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Finally, UBS Group boosted their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $181.40.

Johnson & Johnson Stock Performance

JNJ opened at $185.98 on Friday. The stock has a market cap of $447.91 billion, a PE ratio of 19.89, a P/E/G ratio of 2.37 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $186.59. The stock's 50 day simple moving average is $175.78 and its 200-day simple moving average is $162.66.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the business posted $2.82 earnings per share. The business's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.